biomarkers,details,test_name,test_owner,test_type,indication,secondary,primary_nda,primary_bla,primary_nda1,primary_nda2,primary_bla1,primary_bla2,primary_brand,primary_generic,secondary_nda,secondary_bla,secondary_nda1,secondary_bla1,secondary_brand1,secondary_generic1,secondary_nda2,secondary_brand2,secondary_generic2,secondary_form,secondary_date,primary_form,primary_date
EGFR (HER1),Exon 19 deletion or exon 21 L858R substitution mutation,ONCO/Reveal Dx Lung & Colon Cancer Assay (O/RDx-LCCA),PILLAR,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,0,0,,,,,A TYROSINE KINASE INHIBITOR APPROVED BY FDA FOR THAT INDICATION,,0,0,,,,,,,,,,P200011,07/30/2021
BRCA1 and BRCA2,BRCA1 and BRCA2 alterations,FoundationOne CDx,FOUNDATION,TISSUE,PROSTATE CANCER,,1,0,216793,,,,AKEEGA,NIRAPARIB + ABIRATERONE ACETATE,0,0,,,,,,,,,,P170019/S042,08/11/2023
BRCA1 and BRCA2,BRCA1 and BRCA2 alterations,FoundationOne Liquid CDx,FOUNDATION,PLASMA,METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC),,1,0,216793,,,,AKEEGA,NIRAPARIB +ABIRATERONE ACETATE,0,0,,,,,,,,,,P190032/S014,06/28/ 2024
PDGFRA,D842V mutation,therascreen PDGFRA RGQ PCR Kit,QIAGEN,TISSUE,GASTROINTESTINAL STROMAL TUMORS (GIST),,1,0,212608,,,,AYVAKIT,AVAPRITINIB,0,0,,,,,,,,,,P210002,06/29/2023
ALK,ALK protein expression,Ventana ALK (D5F3) CDx Assay,VENTANA,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,208434,,,,ALECENSA,ALECTINIB,0,0,,,,,,,,,,P140025/S006,11/06/2017
ALK,ALK rearrangements,FoundationOne CDx,FOUNDATION,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,208434,,,,ALECENSA,ALECTINIB,0,0,,,,,,,,,,P170019,11/30/2017
ALK,ALK rearrangements,FoundationOne Liquid CDx,FOUNDATION,PLASMA,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,208434,,,,ALECENSA,ALECTINIB,0,0,,,,,,,,,,P200006,10/26/2020
Concizumab,Tissue factor pathway inhibitor antagonist,ConcizuTrace ELISA,RANDOX,PLASMA,HEMOPHILIA A PATIENTS WITH OR WITHOUT FACTOR VIII INHIBITORS AND HEMOPHILIA B PATIENTS WITH OR WITHOUT IX INHIBITORS,,0,1,,, 761315 , 761428,ALHEMO,CONCIZUMAB,0,0,,,,,,,,,,DEN240035,05/22/2025
ALK,ALK gene rearrangements,Vysis ALK Break Apart FISH Probe Kit,ABBOTT,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,208772,,,,ALUNBRIG,BRIGATINIB,0,0,,,,,,,,,,P110012/S020,05/22/2020
ALK     ,ALK rearrangements     ,FoundationOne CDx,FOUNDATION,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,208772,,,,ALUNBRIG,BRIGATINIB,0,0,,,,,,,,,,P170019/S023,06/30/2021
AAVRh74var capsid neutralizing antibodies,Neutralizing antibodies to the adeno-associated virus serotype Rh74var (AAVRh74var) capsid,nAbCyte Anti-AAVRh74var HB-FE Assay,LABCORP,SERUM,MODERATE TO SEVERE HEMOPHILIA B PATIENTS,,0,1,,, 125786 ,,BEQVEZ,FIDANACOGENE ELAPARVOVEC,0,0,,,,,,,,,,H230005,04/25/2024
BRAF,V600E,MI Cancer Seek (MCS),CARIS,TISSUE,COLORECTAL CANCER, ERBITUX (CETUXIMAB) BLA 125084,1,0,210496,,,,BRAFTOVI,ENCORAFENIB,0,1,, 125084,ERBITUX ,CETUXIMAB,,,,,,P240010,11/05/2024
BRAF,BRAF V600E alteration,FoundationOne Liquid CDx,FOUNDATION,PLASMA,METASTATIC COLORECTAL CANCER (MCRC), CETUXIMAB BLA 125084,1,0,210496,,,,BRAFTOVI,ENCORAFENIB,0,1,, 125084,CETUXIMAB ,,,,,,,P190032/S010,06/08/2023
BRAF,V600E,FoundationOne CDx,FOUNDATION,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC), MEKTOVI (BINIMETINIB) NDA210498,1,0,210496,,,,BRAFTOVI,ENCORAFENIB,1,0,210498,,MEKTOVI ,BINIMETINIB,,,,,,P170019/S039,10/11/2023
BRAF,V600E,FoundationOne Liquid CDx,FOUNDATION,PLASMA,NON-SMALL CELL LUNG CANCER (NSCLC), MEKTOVI (BINIMETINIB) NDA210498,1,0,210496,,,,BRAFTOVI,ENCORAFENIB,1,0,210498,,MEKTOVI ,BINIMETINIB,,,,,,P190032/S011,10/11/2023
FGFR3,"Exon 7: R248C (c.742C>T), S249C (c.746C>G); exon 10: G370C (c.1108G>T) and Y373C (c.1118A>G); and fusions (FGFR3-TACC3v1 and FGFR3-TACC3v3)",therascreen FGFR RGQ RT-PCR Kit,QIAGEN,TISSUE,UROTHELIAL CANCER,,1,0,212018,,,,BALVERSA,ERDAFITINIB,0,0,,,,,,,,,,P180043,04/12/2019
BRAF,V600E,therascreen BRAF V600E RGQ PCR Kit,QIAGEN,TISSUE,COLORECTAL CANCER, ERBITUX (CETUXIMAB) BLA 125084,1,0,210496,,,,BRAFTOVI,ENCORAFENIB,0,1,, 125084,ERBITUX ,CETUXIMAB,,,,,,P190026,04/15/2020
BRAF,V600E or V600K,THXID BRAF Kit,BIOMéRIEUX,TISSUE,MELANOMA, MEKTOVI (BINIMETINIB) NDA 210498,1,0,210496,,,,BRAFTOVI,ENCORAFENIB,1,0, 210498,,MEKTOVI ,BINIMETINIB,,,,,,P120014/S008,06/27/2018
BRAF,V600E or V600K,cobas 4800 BRAF V600 Mutation Test,ROCHE,TISSUE,MELANOMA, ZELBORAF (VEMURAFENIB) NDA 202429,1,0,206192,,,,COTELLIC,COBIMETINIB,1,0, 202429,,ZELBORAF ,VEMURAFENIB,,,,,,P110020/S016,11/07/2016
AAVrh74,Antibodies to the recombinant adeno-associated virus serotype rh74 (AAVrh74) capsid,Quest Diagnostics AAVrh74 Antibody ELISA CDx,QUEST,SERUM,DUCHENNE MUSCULAR DYSTROPHY,,0,1,,, 125781,,ELEVIDYS,DELANDISTROGENE MOXEPARVOVEC-ROKL,0,0,,,,,,,,,,P250002,07/24/2025
ERBB2,ERBB2 Activating Mutations (SNVs And Exon 20 Insertions),Oncomine Dx Target Test,LIFE,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,0,1,,, 761139,,ENHERTU,FAM-TRASTUZUMAB DERUXTECAN-NXKI,0,0,,,,,,,,,,P160045/S035,08/11/2022
ERBB2,ERBB2 Activating Mutations (SNVs And Exon 20 Insertions),Guardant360 CDx,GUARDANT,PLASMA,NON-SMALL CELL LUNG CANCER (NSCLC),,0,1,,, 761139,,ENHERTU,FAM-TRASTUZUMAB DERUXTECAN-NXKI,0,0,,,,,,,,,,P200010/S008,08/11/2022
ALK,ALK gene rearrangements,Vysis ALK Break Apart FISH Probe Kit,ABBOTT,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,218171,,,,ENSACOVE,ENSARTINIB,0,0,,,,,,,,,,P1100212/S022,08/05/2025
FOLR1,FOLR1 protein expression    ,Ventana FOLR1 (FOLR-2.1) RxDx Assay,VENTANA,TISSUE,"EPITHELIAL OVARIAN CANCER, FALLOPIAN TUBE CANCER, OR PRIMARY PERITONEAL CANCER",,0,1,,, 761310,,ELAHERE,MIRVETUXIMAB SORAVTANSINE-GYNX,0,0,,,,,,,,,,P220006,11/14/2022
MET,MET protein expression (>= 50% of tumor cells exhibiting strong membrane and/or cytoplasmic staining 3+),VENTANA MET (SP44) RxDx Assay,VENTANA,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,0,1,,, 761384,,EMRELIS,TELISOTUZUMAB VEDOTIN-TLLV,0,0,,,,,,,,,,P240037,05/14/2025
ERBB2 (HER2),HER2 ultralow expression (IHC 0 with membrane staining),PATHWAY anti-Her2/neu (4B5) Rabbit Monoclonal Primary Antibody,VENTANA,TISSUE,BREAST CANCER,,0,1,,, 761139,,ENHERTU,FAM-TRASTUZUMAB DERUXTECAN-NXKI,0,0,,,,,,,,,,P990081/S055,01/27/2025
ERBB2 (HER2),HER2-low expression (IHC 1+ or IHC 2+/ISH non-amplified),PATHWAY anti-Her2/neu (4B5) Rabbit Monoclonal Primary Antibody,VENTANA,TISSUE,BREAST CANCER,,0,1,,, 761139,,ENHERTU,FAM-TRASTUZUMAB DERUXTECAN-NXKI,0,0,,,,,,,,,,P990081/S047,09/30/2022
EGFR (HER1),EGFR (HER1) protein expression,Dako EGFR pharmDx Kit,DAKO,TISSUE,COLORECTAL CANCER,,0,1,,, 125084,,ERBITUX,CETUXIMAB,0,0,,,,,,,,,,P030044,02/12/2004
KRAS,"G12A, G12D, G12R, G12C, G12S, G12V, G13D",therascreen KRAS RGQ PCR Kit,QIAGEN,TISSUE,COLORECTAL CANCER,,0,1,,, 125084,,ERBITUX,CETUXIMAB,0,0,,,,,,,,,,P110030,07/06/2012
KRAS,KRAS wild-type (absence of mutations in codons 12 and 13),therascreen KRAS RGQ PCR Kit,QIAGEN,TISSUE,COLORECTAL CANCER,,0,1,,, 125084,,ERBITUX,CETUXIMAB,0,0,,,,,,,,,,P110027/S013,12/02/2022
KRAS,KRAS wild-type (absence of mutations in codons 12 and 13),FoundationOne CDx,FOUNDATION,TISSUE,COLORECTAL CANCER,,0,1,,, 125084,,ERBITUX,CETUXIMAB,0,0,,,,,,,,,,P170019,11/30/2017
KRAS,KRAS wild-type (absence of mutations in codons 12 and 13),ONCO/Reveal Dx Lung & Colon Cancer Assay (O/RDx-LCCA),PILLAR,TISSUE,COLORECTAL CANCER,,0,1,,, 125084,,ERBITUX,CETUXIMAB,0,0,,,,,,,,,,P200011,07/30/2021
KRAS,KRAS wild-type (absence of mutations in codons 12 or 13),xT CDx,TEMPUS,TISSUE (MATCHING BLOOD/SALIVA),COLORECTAL CANCER (CRC),,0,1,,, 125084,,ERBITUX,CETUXIMAB,0,0,,,,,,,,,,P210011,04/28/2023
KRAS,Mutations in codons 12 and 13 of KRAS gene,cobas KRAS Mutation Test,ROCHE,TISSUE,COLORECTAL CANCER,,0,1,,, 125084,,ERBITUX,CETUXIMAB,0,0,,,,,,,,,,P140023,05/07/2015
Liver iron concentration imaging,Liver iron concentration based on the proton transverse relaxation rate of MRI images,FerriScan,RESONANCE,TISSUE,NON-TRANSFUSION-DEPENDENT THALASSEMIA,,1,0,021882,,,,EXJADE,DEFERASIROX,0,0,,,,,,,,,,DEN130012 / K124065,01/23/2013
RET,RET fusions,Oncomine Dx Target Test,LIFE,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,213721,,,,GAVRETO,PRALSETINIB,0,0,,,,,,,,,,P160045/S019,09/04/2020
EGFR (HER1),Exon 19 deletion or exon 21 L858R substitution mutation,cobas EGFR Mutation Test v2,ROCHE,TISSUE OR PLASMA,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,201292,,,,GILOTRIF,AFATINIB,0,0,,,,,,,,,,P120019/S031,10/27/2020
EGFR (HER1),Exon 19 deletion or exon 21 L858R substitution mutation,therascreen EGFR RGQ PCR Kit,QIAGEN,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,201292,,,,GILOTRIF,AFATINIB,0,0,,,,,,,,,,P120022,07/12/2013
EGFR (HER1),Exon 19 deletion or exon 21 L858R substitution mutation,FoundationOne CDx,FOUNDATION,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,201292,,,,GILOTRIF,AFATINIB,0,0,,,,,,,,,,P170019,11/30/2017
EGFR (HER1),"L861Q, G719X and S7681",therascreen EGFR RGQ PCR Kit,QIAGEN,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,201292,,,,GILOTRIF,AFATINIB,0,0,,,,,,,,,,P120022/S016,01/12/2016
KIT,D816V,KIT D816V Assay,ARUP,BONE MARROW,AGGRESSIVE SYSTEMIC MASTOCYTOSIS,,1,0,021588,,,,GLEEVEC,IMATINIB MESYLATE,0,0,,,,,,,,,,H140006,12/18/2015
PDGFRB,PDGFRB gene rearrangement at 5q31~33,PDGFRB FISH Assay,ARUP,BONE MARROW,MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE DISEASE,,1,0,021588,,,,GLEEVEC,IMATINIB MESYLATE,0,0,,,,,,,,,,H140005,12/18/2015
ERBB2 (HER2),Activating mutations in the tyrosine kinase domain (SNVs in exons 18-21 and exon 20 insertions),Oncomine Dx Target Test,LIFE,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,219042,,,,HERNEXEOS,ZONGERTINIB,0,0,,,,,,,,,,P160045/S049,08/08/2025
ERBB2 (HER2),ERBB2 (HER2) amplification,FoundationOne CDx,FOUNDATION,TISSUE,BREAST CANCER,,0,1,,, 103792,,HERCEPTIN,TRASTUZUMAB,0,0,,,,,,,,,,P170019,11/30/2017
ERBB2 (HER2),HER-2 protein overexpression,Bond Oracle HER2 IHC System,LEICA,TISSUE,BREAST CANCER,,0,1,,, 103792,,HERCEPTIN,TRASTUZUMAB,0,0,,,,,,,,,,P090015,04/18/2012
ERBB2 (HER2),HER-2 protein overexpression,HercepTest,DAKO,TISSUE,BREAST CANCER,,0,1,,, 103792,,HERCEPTIN,TRASTUZUMAB,0,0,,,,,,,,,,P980018,09/25/1998
ERBB2 (HER2),HER-2 protein overexpression,HercepTest,DAKO,TISSUE,GASTRIC AND GASTROESOPHAGEAL CANCER,,0,1,,, 103792,,HERCEPTIN,TRASTUZUMAB,0,0,,,,,,,,,,P980018/S010,10/20/2010
ERBB2 (HER2),HER-2 protein overexpression,PATHWAY anti-Her2/neu (4B5) Rabbit Monoclonal Primary Antibody,VENTANA,TISSUE,BREAST CANCER,,0,1,,, 103792,,HERCEPTIN,TRASTUZUMAB,0,0,,,,,,,,,,P990081,11/28/2000
ERBB2 (HER2),HER-2/neu (ERBB2) gene amplification,HER2 FISH pharmDx Kit,DAKO,TISSUE,BREAST CANCER,,0,1,,, 103792,,HERCEPTIN,TRASTUZUMAB,0,0,,,,,,,,,,P040005,05/03/2005
ERBB2 (HER2),HER-2/neu (ERBB2) gene amplification,HER2 FISH pharmDx Kit,DAKO,TISSUE,GASTRIC AND GASTROESOPHAGEAL CANCER,,0,1,,, 103792,,HERCEPTIN,TRASTUZUMAB,0,0,,,,,,,,,,P040005/S005,10/20/2010
ERBB2 (HER2),HER-2/neu (ERBB2) gene amplification,SPOT-LIGHT HER2 CISH Kit,LIFE,TISSUE,BREAST CANCER,,0,1,,, 103792,,HERCEPTIN,TRASTUZUMAB,0,0,,,,,,,,,,P050040,07/01/2008
ERBB2 (HER2),HER-2/neu (ERBB2) gene amplification,HER2 CISH pharmDx Kit,DAKO,TISSUE,BREAST CANCER,,0,1,,, 103792,,HERCEPTIN,TRASTUZUMAB,0,0,,,,,,,,,,P100024,11/30/2011
ERBB2 (HER2),HER-2/neu (ERBB2) gene amplification,Ventana HER2 Dual ISH DNA Probe Cocktail,VENTANA,TISSUE,BREAST CANCER,,0,1,,, 103792,,HERCEPTIN,TRASTUZUMAB,0,0,,,,,,,,,,P190031,07/28/2020
ERBB2 (HER2),HER-2/neu (ERBB2) gene amplification,INFORM HER-2/neu,VENTANA,TISSUE,BREAST CANCER,,0,1,,, 103792,,HERCEPTIN,TRASTUZUMAB,0,0,,,,,,,,,,P940004,12/30/1997
ERBB2 (HER2),HER-2/neu (ERBB2) gene amplification,PathVysion HER-2 DNA Probe Kit,ABBOTT,TISSUE,BREAST CANCER,,0,1,,, 103792,,HERCEPTIN,TRASTUZUMAB,0,0,,,,,,,,,,P980024,12/11/1998
ERBB2 (HER2),HER2protein overexpression,InSite Her-2/neu (CB11) Monoclonal Antibody,BIOGENEX,TISSUE,BREAST CANCER,,0,1,,, 103792,,HERCEPTIN,TRASTUZUMAB,0,0,,,,,,,,,,P040030,12/22/2004
PIK3CA,Mutations,FoundationOne Liquid CDx,FOUNDATION,PLASMA,BREAST CANCER, PALBOCICLIB AND FULVESTRANT ,1,0,219249,,,,ITOVEBI,INAVOLISIB,0,0,,,PALBOCICLIB,,,FULVESTRANT ,,,,P190032/S023,10/10/2024
IDH2,"R140Q, R140L, R140G, R140W, R172K, R172M, R172G, R172S, and R172W",Abbott RealTime IDH2,ABBOTT,PERIPHERAL BLOOD OR BONE MARROW,ACUTE MYELOID LEUKEMIA,,1,0,209606,,,,IDHIFA,ENASIDENIB,0,0,,,,,,,,,,P170005,08/01/2017
"POMC, PCSK1 and LEPR",Variants (Pathogenic/Likely Pathogenic) and Variants of Uncertain Significance,POMC/PCSK1/LEPR CDx Panel,PREVENTIONGENETICS,BLOOD OR SALIVA,OBESITY,,1,0,213793,,,,IMCIVREE,SETMELANOTIDE ACETATE,0,0,,,,,,,,,,DEN200059,01/21/2022
Deficient mismatch repair (dMMR) proteins,"MLH1, PMS2, MSH2 and MSH6",Ventana MMR RxDx Panel,VENTANA,TISSUE,ENDOMETRIAL CARCINOMA (EC),,0,1,,, 761069,,IMFINZI,DURVALUMAB,0,0,,,,,,,,,,P210001/S013,12/18/2024
EGFR (HER1),Exon 19 deletion or exon 21 L858R substitution mutation,cobas EGFR Mutation Test v2,ROCHE,TISSUE OR PLASMA,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,206995,,,,IRESSA,GEFITINIB,0,0,,,,,,,,,,P120019/S019,08/22/0218
EGFR (HER1),Exon 19 deletion or exon 21 L858R substitution mutation,cobas EGFR Mutation Test v2,ROCHE,TISSUE OR PLASMA,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,206995,,,,IRESSA,GEFITINIB,0,0,,,,,,,,,,P120019/S031,10/27/2020
EGFR (HER1),Exon 19 deletion or exon 21 L858R substitution mutation,therascreen EGFR RGQ PCR Kit,QIAGEN,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,206995,,,,IRESSA,GEFITINIB,0,0,,,,,,,,,,P120022/S001,07/10/2015
EGFR (HER1),Exon 19 deletion or exon 21 L858R substitution mutation,Oncomine Dx Target Test,LIFE,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,206995,,,,IRESSA,GEFITINIB,0,0,,,,,,,,,,P160045,06/22/2017
EGFR (HER1),Exon 19 deletion or exon 21 L858R substitution mutation,FoundationOne CDx,FOUNDATION,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,206995,,,,IRESSA,GEFITINIB,0,0,,,,,,,,,,P170019,11/30/2017
EGFR (HER1),Exon 19 deletion or exon 21 L858R substitution mutation,FoundationOne Liquid CDx,FOUNDATION,PLASMA,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,206995,,,,IRESSA,GEFITINIB,0,0,,,,,,,,P190032/S008,12/19/2022,P190032,08/26/2020
MSI-High,Microsatellite instability – High (MSI-H),MI Cancer Seek (MCS),CARIS,TISSUE,SOLID TUMORS,,0,1,,, 761223,,JEMPERLI,DOSTARLIMAB-GXLY,0,0,,,,,,,,,,P240010,11/05/2024
Deficient mismatch repair (dMMR) proteins,"MLH1, PMS2, MSH2 and MSH6",Ventana MMR RxDx Panel,VENTANA,TISSUE,ENDOMETRIAL CARCINOMA (EC),,0,1,,, 761174,,JEMPERLI,DOSTARLIMAG-GXLY,0,0,,,,,,,,,,P200019,04/22/2021
Deficient mismatch repair (dMMR) proteins,"MLH1, PMS2, MSH2, and MSH6",Ventana MMR RxDx Panel,VENTANA,SOLID TUMORS,SOLID TUMORS,,0,1,,, 761174,,JEMPERLI,DOSTARLIMAG-GXLY,0,0,,,,,,,,,,P210001,08/17/2021
ERBB2 (HER2),ERBB2 (HER2) amplification,FoundationOne CDx,FOUNDATION,TISSUE,BREAST CANCER,,0,1,,, 125427,,KADCYLA,ADO-TRASTUZUMAB EMTANSINE,0,0,,,,,,,,,,P170019,11/30/2017
ERBB2 (HER2),HER-2 protein overexpression,HercepTest,DAKO,TISSUE,BREAST CANCER,,0,1,,, 125427,,KADCYLA,ADO-TRASTUZUMAB EMTANSINE,0,0,,,,,,,,,,P980018/S016,02/22/2013
ERBB2 (HER2),HER-2 protein overexpression,PATHWAY anti-Her2/neu (4B5) Rabbit Monoclonal Primary Antibody,VENTANA,TISSUE,BREAST CANCER,,0,1,,, 125427,,KADCYLA,ADO-TRASTUZUMAB EMTANSINE,0,0,,,,,,,,,,P990081/S039,05/03/2019
ERBB2 (HER2),HER-2/neu (ERBB2) gene amplification,HER2 FISH pharmDx Kit,DAKO,TISSUE,BREAST CANCER,,0,1,,, 125427,,KADCYLA,ADO-TRASTUZUMAB EMTANSINE,0,0,,,,,,,,,,P040005/S009,02/22/2013
MSI-High,Microsatellite instability – High (MSI-H),MI Cancer Seek (MCS),CARIS,TISSUE,SOLID TUMORS,,0,1,,, 125514,,KEYTRUDA,PEMBROLIZUMAB,0,0,,,,,,,,,,P240010,11/05/2024
MSI-High,Microsatellite instability-High (MSI-H),FoundationOne CDx,FOUNDATION,TISSUE,SOLID TUMORS,,0,1,,, 125514,,KEYTRUDA,PEMBROLIZUMAB,0,0,,,,,,,,,,P170019/S029,02/18/2022
PD-L1,PD-L1 protein expression[Combined Positive Score (CPS) ≥ 10] ,PD-L1 IHC 22C3 pharmDx,DAKO,TISSUE,ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC),,0,1,,, 125514,,KEYTRUDA,PEMBROLIZUMAB,0,0,,,,,,,,,,P150013/S016,07/30/2019
PD-L1,PD-L1 protein expression[Combined Positive Score (CPS) ≥ 10] ,PD-L1 IHC 22C3 pharmDx,DAKO,TISSUE,TRIPLE-NEGATIVE BREAST CANCER (TNBC),,0,1,,, 125514,,KEYTRUDA,PEMBROLIZUMAB,0,0,,,,,,,,,,P150013/S020,11/13/2020
PD-L1,PD-L1 protein expression[Combined Positive Score (CPS) ≥ 1],PD-L1 IHC 22C3 pharmDx,DAKO,TISSUE,CERVICAL CANCER,,0,1,,, 125514,,KEYTRUDA,PEMBROLIZUMAB,0,0,,,,,,,,,,P150013/S009,06/12/2018
PD-L1,PD-L1 protein expression[Combined Positive Score (CPS) ≥ 1],PD-L1 IHC 22C3 pharmDx,DAKO,TISSUE,GASTRIC OR GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA,,0,1,,, 125514,,KEYTRUDA,PEMBROLIZUMAB,0,0,,,,,,,,,,P150013/S027,11/07/2023
PD-L1,PD-L1 protein expression[Combined Positive Score (CPS) ≥ 1] ,PD-L1 IHC 22C3 pharmDx,DAKO,TISSUE,HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC),,0,1,,, 125514,,KEYTRUDA,PEMBROLIZUMAB,0,0,,,,,,,,,,P150013/S014,06/10/2019
PD-L1,PD-L1 protein expression[Tumor Proportion Score (TPS) ≥ 1%],PD-L1 IHC 22C3 pharmDx,DAKO,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,0,1,,, 125514,,KEYTRUDA,PEMBROLIZUMAB,0,0,,,,,,,,P150013/S012,04/16/2019,P150013,10/02/2015
TMB,TMB ≥ 10 mutations per megabase,FoundationOne CDx,FOUNDATION,TISSUE,SOLID TUMORS,,0,1,,, 125514,,KEYTRUDA,PEMBROLIZUMAB,0,0,,,,,,,,,,P170019/S016,06/16/2020
deficient mismatch repair (dMMR) proteins,"MLH1, PMS2, MSH2 and MSH6",Ventana MMR RxDx Panel,VENTANA,SOLID TUMORS,SOLID TUMORS,,0,1,,, 125514,,KEYTRUDA,PEMBROLIZUMAB,0,0,,,,,,,,,,P210001/S001,03/21/2022
Not MSI-High,Not Microsatellite instability-high (Not MSI-H),MI Cancer Seek (MCS),CARIS,TISSUE,ENDOMETRIAL CARCINOMA (EC), LENVIMA (LENVATINIB) NDA 206947,0,1,,, 125514,,KEYTRUDA,PEMBROLIZUMAB,1,0, 206947,,LENVIMA ,LENVATINIB,,,,,,P240010,11/05/2024
proficient mismatch repair (pMMR) proteins ,"MLH1, PMS2, MSH2 and MSH6",Ventana MMR RxDx Panel,VENTANA,TISSUE,ENDOMETRIAL CARCINOMA (EC), LENVIMA (LENVATINIB) NDA 206947,0,1,,, 125514,,KEYTRUDA,PEMBROLIZUMAB,1,0, 206947,,LENVIMA ,LENVATINIB,,,,,,P210001/S002,06/16/2022
HLA,HLA-A*02:01,SeCore CDx HLA Sequencing System,ONE,WHOLE BLOOD,UVEAL MELANOMA,,0,1,,, 761228,,KIMMTRAK,TEBENTAFUSP-TEBN,0,0,,,,,,,,,,BR220737,11/28/2022
KRAS,KRAS G12C,therascreen KRAS RGQ PCR Kit,QIAGEN,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,216340,,,,KRAZATI,ADAGRASIB,0,0,,,,,,,,,,P110027/S013,12/02/2022
KRAS,KRAS G12C,Agilent Resolution ctDx FIRST assay,RESOLUTION,PLASMA,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,216340,,,,KRAZATI,ADAGRASIB,0,0,,,,,,,,,,P210040,12/12/2022
KRAS,KRAS G12C,therascreen KRAS RGQ PCR Kit,QIAGEN,TISSUE,COLORECTAL CANCER, ERBITUX (CETUXIMAB) – NDA 216340,0,0,,,,,KRAZATI,ADAGRASIB,1,0, 216340,,ERBITUX ,CETUXIMAB,,,,,,P110027/S017,06/21/2024
PD-L1,PD-L1 protein expression [Tumor Proportion Score (TPS) ≥ 50%],PD-L1 IHC 22C3 pharmDx,DAKO,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,0,1,,, 761097,,LIBTAYO,CEMIPLIMAB-RWLC,0,0,,,,,,,,,,P150013/S021,02/22/2021
PD-L1,PD-L1 protein expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%]),Ventana PD-L1 (SP263) Assay,VENTANA,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,0,1,,, 761097,,LIBTAYO,CEMIPLIMAB-RWLC,0,0,,,,,,,,,,P160046/S013,03/01/2023
ALK,ALK protein expression,Ventana ALK (D5F3) CDx Assay,VENTANA,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,210868,,,,LORBRENA,LORLATINIB,0,0,,,,,,,,,,P140025/S014,03/03/2021
KRAS,G12C,therascreen KRAS RGQ PCR Kit,QIAGEN,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,214665,,,,LUMAKRAS,SOTORASIB,0,0,,,,,,,,,,P110027/S012,05/28/2021
KRAS,G12C,Guardant360 CDx,GUARDANT,PLASMA,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,214665,,,,LUMAKRAS,SOTORASIB,0,0,,,,,,,,,,P200010/S002,05/28/2021
KRAS ,KRAS G12C ,therascreen KRAS RGQ PCR Kit,QIAGEN,TISSUE,COLORECTAL CANCER, VECTIBIX (PANITUMUMAB) – BLA 125147  ,1,0,214665,,,,LUMAKRAS,SOTORASIB,0,1,, 125147  ,VECTIBIX ,PANITUMUMAB,,,,,,P110027/S018,01/16/2025
"BRCA1, BRCA2 and ATM","BRCA1, BRCA2, and ATM alterations",FoundationOne Liquid CDx,FOUNDATION,PLASMA,METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC),,1,0,208558,,,,LYNPARZA,OLAPARIB,0,0,,,,,,,,,,P200016,11/06/2020
BRCA1 and BRCA2,BRCA1 and BRCA2 alterations,FoundationOne CDx,FOUNDATION,TISSUE,OVARIAN CANCER,,1,0,208558,,,,LYNPARZA,OLAPARIB,0,0,,,,,,,,,,P170019/S004,07/01/2019
BRCA1 and BRCA2,Mutations,BRACAnalysis CDx,MYRIAD,WHOLE BLOOD,OVARIAN CANCER,,1,0,208558,,,,LYNPARZA,OLAPARIB,0,0,,,,,,,,,,P140020,12/19/2014
BRCA1 and BRCA2,Mutations,BRACAnalysis CDx,MYRIAD,WHOLE BLOOD,BREAST CANCER,,1,0,208558,,,,LYNPARZA,OLAPARIB,0,0,,,,,,,,,,P140020/S012,01/12/2018
BRCA1 and BRCA2,Mutations,BRACAnalysis CDx,MYRIAD,WHOLE BLOOD,PANCREATIC CANCER,,1,0,208558,,,,LYNPARZA,OLAPARIB,0,0,,,,,,,,,,P140020/S019,12/27/2019
BRCA1 and BRCA2,Mutations,BRACAnalysis CDx,MYRIAD,WHOLE BLOOD,METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC),,1,0,208558,,,,LYNPARZA,OLAPARIB,0,0,,,,,,,,,,P140020/S020,05/19/2020
Homologous recombination repair (HRR) genes,"BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D and RAD54L alterations",FoundationOne CDx,FOUNDATION,TISSUE,METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC),,1,0,208558,,,,LYNPARZA,OLAPARIB,0,0,,,,,,,,,,P170019/S015,05/19/2020
Myriad HRD,Deleterious or suspected deleterious mutations in BRCA1 and BRCA2 genes and/or positive Genomic Instability Score),Myriad myChoice CDx,MYRIAD,TISSUE,OVARIAN CANCER,,1,0,208558,,,,LYNPARZA,OLAPARIB,0,0,,,,,,,,,,P190014/S003,05/08/2020
BRCA1 and BRCA2,BRCA1 and BRCA2 alterations,FoundationOne CDx,FOUNDATION,TISSUE,METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC), ABIRATERONE ,1,0,208558,,,,LYNPARZA,OLAPARIB,0,0,,,ABIRATERONE ,,,,,,,P170019/S052,08/30/2024
BRCA1 and BRCA2,BRCA1 and BRCA2 alterations,FoundationOne Liquid CDx,FOUNDATION,PLASMA,METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC), ABIRATERONE ,1,0,208558,,,,LYNPARZA,OLAPARIB,0,0,,,ABIRATERONE ,,,,,,,P190032/S016,08/30/2024
BRAF,V600E and V600K,FoundationOne CDx,FOUNDATION,TISSUE,MELANOMA,,1,0,204114,,,,MEKINIST,TRAMETINIB,0,0,,,,,,,,,,P170019,11/30/2017
BRAF,V600E or V600K,THXID BRAF Kit,BIOMéRIEUX,TISSUE,MELANOMA,,1,0,204114,,,,MEKINIST,TRAMETINIB,0,0,,,,,,,,,,P120014,05/29/2013
BRAF,V600E or V600K,MI Cancer Seek (MCS),CARIS,TISSUE,MELANOMA,,1,0,204114,,,,MEKINIST,TRAMETINIB,0,0,,,,,,,,,,P240010,11/05/2024
"ACVR2A, BTBD7, DIDO1, MRE11, RYR3, SEC31A and SULF2",Microsatellite instability-High (MSI-H),Idylla CDx MSI Test,BIOCARTIS,TISSUE,COLORECTAL CANCER (CRC),,0,1,,, 125554,,OPDIVO,NIVOLUMAB,0,0,,,,,,,,,,P250005,08/15/2025
"ACVR2A, BTBD7, DIDO1, MRE11, RYR3, SEC31A and SULF2",Microsatellite instability-High (MSI-H),Idylla CDx MSI Test,BIOCARTIS,TISSUE,COLORECTAL CANCER (CRC), YERVOY (IPILIMUMAB) BLA 125377,0,0,,,,,OPDIVO,NIVOLUMAB,0,1,, 125377,YERVOY ,IPILIMUMAB,,,,,,P250005,08/15/2025
Deficient mismatch repair (dMMR) proteins,"MLH1, PMS2, MSH2 and MSH6",MMR IHC Panel pharmDx (Dako Omnis),AGILENT,TISSUE,COLORECTAL CANCER (CRC),,0,1,,, 125554,,OPDIVO,NIVOLUMAB,0,0,,,,,,,,,,P250004,08/15/2025
Deficient mismatch repair (dMMR) proteins,"MLH1, PMS2, MSH2 and MSH6",MMR IHC Panel pharmDx (Dako Omnis),AGILENT,TISSUE,COLORECTAL CANCER (CRC), YERVOY (IPILIMUMAB) BLA 125377,0,0,,,,,OPDIVO,NIVOLUMAB,0,1,, 125377,YERVOY ,IPILIMUMAB,,,,,,P250004,08/15/2025
BRAF,BRAF V600 mutations and BRAF fusions,FoundationOne CDx,FOUNDATION,TISSUE,LOW-GRADE GLIOMA,,1,0,217700,218033,,,OJEMDA,TOVORAFENIB,0,0,,,,,,,,,,P170019/S054,01/16/2025
PD-L1,PD-L1 protein expression (tumor cell staining ≥1%),PD-L1 IHC 28-8 pharmDx,DAKO,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC), YERVOY (IPILIMUMAB) BLA 125377,0,1,,, 125554,,OPDIVO,NIVOLUMAB,0,1,, 125377,YERVOY ,IPILIMUMAB,,,,,,P150025/S013,05/15/2020
ESR1,ESR1 missense mutations between codons 310 and 547,Guardant360 CDx,GUARDANT,PLASMA,BREAST CANCER,,1,0,217639,,,,ORSERDU,ELACESTRANT,0,0,,,,,,,,,,P200010/S010,01/27/2023
FGFR2,FGFR2 fusions and select rearrangements,FoundationOne CDx,FOUNDATION,TISSUE,CHOLANGIOCARCINOMA,,1,0,213736,,,,PEMAZYRE,PEMIGATINIB,0,0,,,,,,,,,,P170019/S013,04/17/2020
ERBB2 (HER2),ERBB2 (HER2) amplification,FoundationOne CDx,FOUNDATION,TISSUE,BREAST CANCER,,0,1,,, 125409,,PERJETA,PERTUZUMAB,0,0,,,,,,,,,,P170019,11/30/2017
ERBB2 (HER2),HER-2 protein overexpression,HercepTest,DAKO,TISSUE,BREAST CANCER,,0,1,,, 125409,,PERJETA,PERTUZUMAB,0,0,,,,,,,,,,P980018/S015,06/08/2012
ERBB2 (HER2),HER-2/neu (ERBB2) gene amplification,HER2 FISH pharmDx Kit,DAKO,TISSUE,BREAST CANCER,,0,1,,, 125409,,PERJETA,PERTUZUMAB,0,0,,,,,,,,,,P040005/S006,06/08/2012
PIK3CA,"C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047Y",FoundationOne CDx,FOUNDATION,TISSUE,BREAST CANCER,,1,0,212526,,,,PIQRAY,ALPELISIB,0,0,,,,,,,,,,P170019/S006,12/03/2019
PIK3CA,"C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047Y",therascreen PIK3CA RGQ PCR Kit,QIAGEN,TISSUE OR PLASMA,BREAST CANCER,,1,0,212526,,,,PIQRAY,ALPELISIB,0,0,,,,,,,,P190004,05/24/2019,P190001,05/24/2019
PIK3CA,"C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047Y",FoundationOne Liquid CDx,FOUNDATION,PLASMA,BREAST CANCER,,1,0,212526,,,,PIQRAY,ALPELISIB,0,0,,,,,,,,,,P200006,10/26/2020
PIK3CA,"C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047Y",MI Cancer Seek (MCS),CARIS,TISSUE,BREAST CANCER,,1,0,212526,,,,PIQRAY,ALPELISIB,0,0,,,,,,,,,,P240010,11/05/2024
Antithrombin III,Functionally active Antithrombin III,INNOVANCE Antithrombin,SIEMENS,PLASMA,HEMOPHILIA A PATIENTS WITH OR WITHOUT FACTOR VIII INHIBITORS AND HEMOPHILIA B PATIENTS WITH OR WITHOUT IX INHIBITORS,,1,0,219019,,,,QFITLIA,FITUSIRAN,0,0,,,,,,,,,,K242952,03/28/2025
RET,RET fusions,FoundationOne CDx,FOUNDATION,TISSUE,SOLID TUMORS,,1,0,214246,,,,RETEVMO,SELPERCATINIB,0,0,,,,,,,,,,P170019/S043,10/06/2023
Anti-AAV5 Antibodies,Antibodies to the adeno-associated virus serotype 5 (AAV5) viral vector,AAV5 DetectCDx,ARUP,PLASMA,HEMOPHILIA A PATIENTS,,0,1,,, 125720,,ROCTAVIAN,VALOCTOCOGENE ROXAPARVOVEC-RVOX,0,0,,,,,,,,,,P190033,06/29/2023
RET,RET fusions,Oncomine Dx Target Test,LIFE,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,213246,,,,RETEVMO,SELPERCATINIB,0,0,,,,,,,,,,P160045/S031,09/21/2022
RET,RET fusions,Oncomine Dx Target Test,LIFE,TISSUE,THYROID CANCER (TC),,1,0,213246,,,,RETEVMO,SELPERCATINIB,0,0,,,,,,,,,,P160045/S031,09/21/2022
RET,RET fusions,TruSight Oncology Comprehensive,ILLUMINA,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,213246,,,,RETEVMO,SELPERCATINIB,0,0,,,,,,,,,,P230011,08/21/2024
RET,"RET mutations (SNVs, MNVs, and deletions)",Oncomine Dx Target Test,LIFE,TISSUE,MEDULLARY THYROID CANCER (MTC),,1,0,213246,,,,RETEVMO,SELPERCATINIB,0,0,,,,,,,,,,P160045/S031,09/21/2022
IDH1,"R132 mutations (R132C, R132H, R132G, R132S, and R132L)",Abbott RealTime IDH1,ABBOTT,PERIPHERAL BLOOD OR BONE MARROW,ACUTE MYELOID LEUKEMIA,,1,0,215814,,,,REZLIDHIA,OLUTASIDENIB,0,0,,,,,,,,,,P170041/S006,12/01/2022
"NTRK1, NTRK2, and NTRK3 fusions",NTRK1/2/3 fusions,FoundationOne Liquid CDx,FOUNDATION,PLASMA,SOLID TUMORS,,1,0,212725,,,,ROZLYTREK,ENTRECTINIB,0,0,,,,,,,,,,P190032/S004,12/22/2022
ROS1,ROS1 fusions,FoundationOne Liquid CDx,FOUNDATION,PLASMA,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,212725,,,,ROZLYTREK,ENTRECTINIB,0,0,,,,,,,,,,P190032/S004,12/22/2022
"NTRK1, NTRK2 and NTRK3    ","NTRK1, NTRK2 and NTRK3 fusions",FoundationOne CDx,FOUNDATION,TISSUE,SOLID TUMORS,,1,0,212725,,,,ROZLYTREK,ENTRECTINIB,0,0,,,,,,,,,,P170019/S014,06/07/2022
ROS1,ROS1 fusions,FoundationOne CDx,FOUNDATION,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,212725,,,,ROZLYTREK,ENTRECTINIB,0,0,,,,,,,,,,P170019/S014,06/07/2022
BRCA1 and BRCA2,BRCA1 and BRCA2 alterations,FoundationFocus CDxBRCA Assay,FOUNDATION,TISSUE,OVARIAN CANCER,,1,0,209115,,,,RUBRACA,RUCAPARIB,0,0,,,,,,,,,,P160018,12/19/2016
BRCA1 and BRCA2,BRCA1 and BRCA2 alterations,FoundationOne Liquid CDx,FOUNDATION,PLASMA,METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC),,1,0,209115,,,,RUBRACA,RUCAPARIB,0,0,,,,,,,,,,P190032,08/26/2020
BRCA1 and BRCA2,Mutations,BRACAnalysis CDx,MYRIAD,WHOLE BLOOD,OVARIAN CANCER,,1,0,209115,,,,RUBRACA,RUCAPARIB,0,0,,,,,,,,,,P140020/S016,10/16/2018
EGFR (HER1),EGFR exon 20 insertions,Guardant360 CDx,GUARDANT,PLASMA,NON-SMALL CELL LUNG CANCER (NSCLC),,0,1,,, 761210,,RYBREVANT,AMIVANTAMB,0,0,,,,,,,,,,P200010/S001,05/21/2021
EGFR (HER1),Exon 20 insertion mutations,Oncomine Dx Target Test,LIFE,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,0,1,,, 761210,,RYBREVANT,AMIVANTAMB,0,0,,,,,,,,,,P160045/S027,12/01/2021
FLT3 (ITD/TDK),ITD mutations and TKD mutations D835 and I836,LeukoStrat CDx FLT3 Mutation Assay,INVIVOSCRIBE,PERIPHERAL BLOOD OR BONE MARROW,ACUTE MYELOGENOUS LEUKEMIA,,1,0,207997,,,,RYDAPT,MIDOSTAURIN,0,0,,,,,,,,,,P160040,04/28/2017
"PIK3CA, AKT1, and PTEN",PIK3CA/AKT1/PTEN alterations,FoundationOne CDx,FOUNDATION,TISSUE,BREAST CANCER, FASLODEX (FULVESTRANT) NDA021344,1,0,218197,,,,TRUQAP,CAPIVASERTIB,1,0,021344,,FASLODEX ,FULVESTRANT,,,,,,P170019/S048,11/16/2023
MET,MET single nucleotide variants and indels that lead to MET exon 14 skipping,FoundationOne CDx,FOUNDATION,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,213591,,,,TABRECTA,CAPMATINIB,0,0,,,,,,,,,,P170019/S011,05/06/2020
MET,MET single nucleotide variants and indels that lead to MET exon 14 skipping,FoundationOne Liquid CDx,FOUNDATION,PLASMA,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,213591,,,,TABRECTA,CAPMATINIB,0,0,,,,,,,,,,P190032/S001,07/15/2021
BRAF,V600E,THXID BRAF Kit,BIOMéRIEUX,TISSUE,MELANOMA,,1,0,202806,,,,TAFINLAR,DABRAFENIB,0,0,,,,,,,,,,P120014,05/29/2013
BRAF,BRAF V600E mutations,Oncomine Dx Target Test,LIFE,TISSUE,ANAPLASTIC THYROID CANCER (ATC), MEKINIST (TRAMETINIB) NDA 204114,1,0,202806,,,,TAFINLAR,DABRAFENIB,1,0, 204114,,MEKINIST ,TRAMETINIB,,,,,,P160045/S025,09/29/2023
BRAF,V600E,Oncomine Dx Target Test,LIFE,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC), MEKINIST (TRAMETINIB) NDA 204114,1,0,202806,,,,TAFINLAR,DABRAFENIB,1,0, 204114,,MEKINIST ,TRAMETINIB,,,,,,P160045,06/22/2017
BRAF,V600E,FoundationOne CDx,FOUNDATION,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC), MEKINIST (TRAMETINIB) NDA 204114,1,0,202806,,,,TAFINLAR,DABRAFENIB,1,0, 204114,,MEKINIST ,TRAMETINIB,,,,,,P170019,11/30/2017
EGFR (HER1),"EGFR exon 19 deletions, EGFR exon 21 L858R, and T790M",Guardant360 CDx,GUARDANT,PLASMA,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,208065,,,,TAGRISSO,OSIMERTINIB,0,0,,,,,,,,,,P200010,08/07/2020
EGFR (HER1),Exon 19 deletion or exon 21 L858R substitution mutation,cobas EGFR Mutation Test v2,ROCHE,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,208065,,,,TAGRISSO,OSIMERTINIB,0,0,,,,,,,,,,P120019/S016,04/18/2018
EGFR (HER1),Exon 19 deletion or exon 21 L858R substitution mutation,cobas EGFR Mutation Test v2,ROCHE,PLASMA,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,208065,,,,TAGRISSO,OSIMERTINIB,0,0,,,,,,,,,,P120019/S018,04/18/2018
EGFR (HER1),Exon 19 deletion or exon 21 L858R substitution mutation,cobas EGFR Mutation Test v2,ROCHE,TISSUE OR PLASMA,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,208065,,,,TAGRISSO,OSIMERTINIB,0,0,,,,,,,,,,P120019/S031,10/27/2020
EGFR (HER1),Exon 19 deletion or exon 21 L858R substitution mutation,FoundationOne CDx,FOUNDATION,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,208065,,,,TAGRISSO,OSIMERTINIB,0,0,,,,,,,,,,P170019/S008,07/01/2019
EGFR (HER1),Exon 19 deletion or exon 21 L858R substitution mutation,FoundationOne Liquid CDx,FOUNDATION,PLASMA,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,208065,,,,TAGRISSO,OSIMERTINIB,0,0,,,,,,,,P190032/S008,12/19/2022,P190032,08/26/2020
EGFR (HER1),T790M,cobas EGFR Mutation Test v2,ROCHE,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,208065,,,,TAGRISSO,OSIMERTINIB,0,0,,,,,,,,,,P120019/S007,11/13/2015
EGFR (HER1),T790M,cobas EGFR Mutation Test v2,ROCHE,PLASMA,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,208065,,,,TAGRISSO,OSIMERTINIB,0,0,,,,,,,,,,P150044,09/28/2016
EGFR (HER1),T790M,FoundationOne CDx,FOUNDATION,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,208065,,,,TAGRISSO,OSIMERTINIB,0,0,,,,,,,,,,P170019,11/30/2017
BRCA1 and BRCA2,Mutations,BRACAnalysis CDx,MYRIAD,WHOLE BLOOD,BREAST CANCER,,1,0,211651,,,,TALZENNA,TALAZOPARIB,0,0,,,,,,,,,,P140020/S015,10/16/2018
EGFR (HER1),Exon 19 deletion or exon 21 L858R substitution mutation,cobas EGFR Mutation Test v1,ROCHE,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,021743,,,,TARCEVA,ERLOTINIB,0,0,,,,,,,,,,P120019,07/15/2013
EGFR (HER1),Exon 19 deletion or exon 21 L858R substitution mutation,cobas EGFR Mutation Test v2,ROCHE,TISSUE OR PLASMA,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,021743,,,,TARCEVA,ERLOTINIB,0,0,,,,,,,,,,P120019/S031,10/27/2020
EGFR (HER1),Exon 19 deletion or exon 21 L858R substitution mutation,cobas EGFR Mutation Test v2,ROCHE,PLASMA,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,021743,,,,TARCEVA,ERLOTINIB,0,0,,,,,,,,,,P150047,06/01/2016
EGFR (HER1),Exon 19 deletion or exon 21 L858R substitution mutation,FoundationOne CDx,FOUNDATION,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,021743,,,,TARCEVA,ERLOTINIB,0,0,,,,,,,,,,P170019,11/30/2017
EGFR (HER1),Exon 19 deletion or exon 21 L858R substitution mutation,FoundationOne Liquid CDx,FOUNDATION,PLASMA,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,021743,,,,TARCEVA,ERLOTINIB,0,0,,,,,,,,P190032/S008,12/19/2022,P190032,08/26/2020
t(9;21) Philadelphia chromosome,BCR-ABL fusion,MRDx BCR-ABL Test,MOLECULARMD,PERIPHERAL BLOOD,CHRONIC MYELOID LEUKEMIA,,1,0,022068,,,,TASIGNA,NILOTINIB,0,0,,,,,,,,,,K173492,12/22/2017
EZH2,"Y646N, Y646F or Y646X (Y646H, Y646S, or Y646C), A682G, and A692V of the EZH2 gene",cobas EZH2 Mutation Test,ROCHE,TISSUE,FOLLICULAR LYMPHOMA TUMOR,,1,0,213400,,,,TAZVERIK,TAZEMETOSTAT,0,0,,,,,,,,,,P200014,06/18/2020
HLA,"Eligible alleles: HLA-A*02:01, HLA-A*02:02, HLA-A*02:03 or HLA-A*02:06 and their P-group alleles.Exclusion alleles: HLA-A*02:05 and its P-group alleles.    ",SeCore CDx HLA Sequencing System,ONE,WHOLE BLOOD,SYNOVIAL SARCOMA,,0,1,,, 125789,,TECELRA,AFAMITRESGENE AUTOLEUCEL,0,0,,,,,,,,,,BK241074,08/01/2024
Melanoma-associated antigen 4 (MAGE-A4),MAGE-A4 protein overexpression,MAGE-A4 IHC 1F9 pharmDx,AGILENT,TISSUE,SYNOVIAL SARCOMA,,0,1,,, 125789,,TECELRA,AFAMITRESGENE AUTOLEUCEL,0,0,,,,,,,,,,P230016,08/01/2024
PD-L1,PD-L1 protein expression (PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 5% of the tumor area),Ventana PD-L1 (SP142) Assay,VENTANA,TISSUE,UROTHELIAL CARCINOMA,,0,1,,, 761034,,TECENTRIQ,ATEZOLIZUMAB,0,0,,,,,,,,,,P160002,05/18/2016
PD-L1,PD-L1 protein expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]),Ventana PD-L1 (SP142) Assay,VENTANA,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,0,1,,, 761034,,TECENTRIQ,ATEZOLIZUMAB,0,0,,,,,,,,,,P160002/S006,07/02/2018
PD-L1,PD-L1 protein expression(PD-L1 stained ≥ 1% of tumor cells [TC ≥ 1%]),Ventana PD-LI (SP263) Assay,VENTANA,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,0,1,,, 761034,,TECENTRIQ,ATEZOLIZUMAB,0,0,,,,,,,,,,P160046/S010,10/15/2021
BRAF,BRAF V600 mutations,FoundationOne CDx,FOUNDATION,TISSUE,MELANOMA, COTELLIC (COBIMETINIB) NDA 206192 AND ZELBORAF (VEMURAFENIB) NDA 202429,0,1,,, 761034,,TECENTRIQ,ATEZOLIZUMAB,1,0, 206192,,COTELLIC ,COBIMETINIB, 202429,ZELBORAF ,VEMURAFENIB,,,P170019/S030,01/19/2022
MET,MET single nucleotide variants and indels that lead to MET exon 14 skipping,FoundationOne Liquid CDx,FOUNDATION,PLASMA,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,214096,,,,TEPMETKO,TEPOTINIB,0,0,,,,,,,,,,P190032/S015,11/14/2024
IDH1,"R132 mutations (R132C, R132H, R132G, R132S, and R132L)",Abbott RealTime IDH1,ABBOTT,PERIPHERAL BLOOD OR BONE MARROW,ACUTE MYELOID LEUKEMIA,,1,0,211192,,,,TIBSOVO,IVOSIDENIB,0,0,,,,,,,,,,P170041,07/20/2018
IDH1,"R132 mutations (R132C, R132H, R132G, R132S, and R132L)",Abbott RealTime IDH1,ABBOTT,PERIPHERAL BLOOD OR BONE MARROW,MYELODYSPLASTIC SYNDROMES (MDS),,1,0,211192,,,,TIBSOVO,IVOSIDENIB,0,0,,,,,,,,,,P170041/S007,10/24/2023
IDH1,Single nucleotide variants,Oncomine Dx Target Test,LIFE,TISSUE,CHOLANGIOCARCINOMA,,1,0,211192,,,,TIBSOVO,IVOSIDENIB,0,0,,,,,,,,,,P160045/S028,08/25/2021
FLT3 (ITD/TDK),IDT mutations and TKD mutations D835 and I836,LeukoStrat CDx FLT3 Mutation Assay,INVIVOSCRIBE,PERIPHERAL BLOOD OR BONE MARROW,ACUTE MYELOGENOUS LEUKEMIA (AML),,1,0,216993,,,,VANFLYTA,QUIZARTINIB,0,0,,,,,,,,,,P160040/S011,07/20/2023
"IDH1, IDH2","IDH1 R132C, IDH1 R132G, IDH1 R132H, IDH1 R132L, IDH1 R132S, IDH2 R172M, IDH2 R172K, IDH2 R172W, IDH2 R172S, and IDH2 R172G mutations",Oncomine Dx Target Test,LIFE,TISSUE,ASTROCYTOMA AND OLIGODENDROGLIOMA,,1,0,218784,,,,VORANIGO,VORASIDENIB,0,0,,,,,,,,,,P160045/S046,09/18/2024
Claudin 18 (CLDN18),Claudin 18 (CLDN18) protein expression (≥75% viable tumor cells (% TC) staining) ,VENTANA CLDN18 (43-14A) RxDx Assay,VENTANA,TISSUE,GASTRIC OR GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA,,0,1,,, 761365,,VYLOY,ZOLBETUXIMAB,0,0,,,,,,,,,,P230018,10/18/2024
EGFR (HER1),EGFR (HER1) protein expression,Dako EGFR pharmDx Kit,DAKO,TISSUE,COLORECTAL CANCER,,0,1,,, 125147,,VECTIBIX,PANITUMUMAB,0,0,,,,,,,,,,P030044/S002,09/27/2006
KRAS,"G12A, G12D, G12R, G12C, G12S, G12V, G13D",therascreen KRAS RGQ PCR Kit,QIAGEN,TISSUE,COLORECTAL CANCER,,0,1,,, 125147,,VECTIBIX,PANITUMUMAB,0,0,,,,,,,,,,P110027,05/23/2014
KRAS,KRAS wild-type (absence of mutations in codons 12 and 13),ONCO/Reveal Dx Lung & Colon Cancer Assay (O/RDx-LCCA),PILLAR,TISSUE,COLORECTAL CANCER,,0,1,,, 125147,,VECTIBIX,PANITUMUMAB,0,0,,,,,,,,,,P200011,07/30/2021
KRAS,Mutations in codons 12 and 13 of KRAS gene,cobas KRAS Mutation Test,ROCHE,TISSUE,COLORECTAL CANCER,,0,1,,, 125147,,VECTIBIX,PANITUMUMAB,0,0,,,,,,,,,,P140023,05/07/2015
KRAS and NRAS,"KRAS wild-type (absence of mutations in exons 2, 3, and 4) and NRAS wild type (absence of mutations in exons 2, 3, and 4)",FoundationOne CDx,FOUNDATION,TISSUE,COLORECTAL CANCER,,0,1,,, 125147,,VECTIBIX,PANITUMUMAB,0,0,,,,,,,,,,P170019,11/30/2017
KRAS and NRAS,"KRAS wild-type (absence of mutations in exons 2, 3, or 4) and NRAS wild-type (absence of mutations in exons 2, 3, or 4)",xT CDx,TEMPUS,TISSUE (MATCHING BLOOD/SALIVA),COLORECTAL CANCER (CRC),,0,1,,, 125147,,VECTIBIX,PANITUMUMAB,0,0,,,,,,,,,,P210011,04/28/2023
KRAS and NRAS,"KRAS wild-type biomarkers (the absence of mutations in exons 2, 3, or 4) and NRAS wild-type biomarkers (the absence of mutations in exons 2, 3, or 4)",CRCDx RAS Mutation Detection Assay Kit,ENTROGEN,TISSUE,COLORECTAL CANCER (CRC),,0,1,,, 125147,,VECTIBIX,PANITUMUMAB,0,0,,,,,,,,,,P220005,09/29/2023
KRAS and NRAS,"KRAS wild-type biomarkers (the absence of mutations in exons 2, 3, or 4) and NRAS wild-type biomarkers (the absence of mutations in exons 2, 3, or 4)",MI Cancer Seek (MCS),CARIS,TISSUE,COLORECTAL CANCER,,0,1,,, 125147,,VECTIBIX,PANITUMUMAB,0,0,,,,,,,,,,P240010,11/05/2024
TP53,Deletion chromosome 17p (17p-),Vysis CLL FISH Probe Kit,ABBOTT,PERIPHERAL BLOOD,B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA,,1,0,208573,,,,VENCLEXTA,VENETOCLAX,0,0,,,,,,,,,,P150041,04/11/2016
"NTRK1, NTRK2 and NTRK3","NTRK1, NTRK2 and NTRK3 fusions",FoundationOne CDx,FOUNDATION,TISSUE,SOLID TUMORS,,1,0,210861,,,,VITRAKVI,LAROTRECTINIB,0,0,,,,,,,,,,P170019/S017,10/23/2020
"NTRK1, NTRK2, and NTRK3 fusions",NTRK1/2/3 fusions,TruSight Oncology Comprehensive,ILLUMINA,TISSUE,SOLID TUMORS,,1,0,210861,,,,VITRAKVI,LAROTRECTINIB,0,0,,,,,,,,,,P230011,08/21/2024
EGFR (HER1),Exon 19 deletion or exon 21 L858R substitution mutation,therascreen EGFR RGQ PCR Kit,QIAGEN,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,211288,,,,VIZIMPRO,DACOMITINIB,0,0,,,,,,,,,,P120022/S018,09/27/2018
ALK,ALK gene rearrangements,Vysis ALK Break Apart FISH Probe Kit,ABBOTT,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,202570,,,,XALKORI,CRIZOTINIB,0,0,,,,,,,,,,P110012,08/26/2011
ALK,ALK protein expression,Ventana ALK (D5F3) CDx Assay,VENTANA,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,202570,,,,XALKORI,CRIZOTINIB,0,0,,,,,,,,,,P140025,06/12/2015
ALK,ALK rearrangements,FoundationOne CDx,FOUNDATION,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,202570,,,,XALKORI,CRIZOTINIB,0,0,,,,,,,,,,P170019,11/30/2017
ROS1,ROS1 fusions,Oncomine Dx Target Test,LIFE,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,202570,,,,XALKORI,CRIZOTINIB,0,0,,,,,,,,,,P160045,06/22/2017
FLT3 (ITD/TDK),ITD mutations and TKD mutations D835 and I836,LeukoStrat CDx FLT3 Mutation Assay,INVIVOSCRIBE,PERIPHERAL BLOOD OR BONE MARROW,ACUTE MYELOGENOUS LEUKEMIA,,1,0,211349,,,,XOSPATA,GILTERINIB,0,0,,,,,,,,,,P160040/S002,11/28/2018
EGFR,Exon 20 insertion mutations,Oncomine Dx Express Test,LIFE,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,219839,,,,ZEGFROVY,SUNVOZERTINIB,0,0,,,,,,,,,,P240040,07/02/2025
BRAF,V600E,cobas 4800 BRAF V600 Mutation Test,ROCHE,TISSUE,MELANOMA,,1,0,202429,,,,ZELBORAF,VEMURAFENIB,0,0,,,,,,,,,,P110020,08/17/2011
ERBB2 (HER2),HER-2 protein overexpression,PATHWAY anti-Her2/neu (4B5) Rabbit Monoclonal Primary Antibody,VENTANA,TISSUE,"BILIARY TRACT CANCER (GALLBLADDER ADENOCARCINOMA, INTRAHEPATIC CHOLANGIOCARCINOMA, AND EXTRAHEPATIC CHOLANGIOCARCINOMA)",,0,1,,, 761416,,ZIIHERA,ZANIDATAMAB-HRII,0,0,,,,,,,,,,P990081/S054,11/20/2024
ALK,ALK protein expression,Ventana ALK (D5F3) CDx Assay,VENTANA,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,211225,,,,ZYKADIA,CERITINIB,0,0,,,,,,,,,,P140025/S005,05/26/2017
ALK,ALK rearrangements,FoundationOne CDx,FOUNDATION,TISSUE,NON-SMALL CELL LUNG CANCER (NSCLC),,1,0,211225,,,,ZYKADIA,CERITINIB,0,0,,,,,,,,,,P170019,11/30/2017
